US · KEQU · FURNISHINGS, FIXTURES & APPLIANCES
Kewaunee Scientific Corporation (KEQU) intrinsic value and stock valuation
$33.55as of 2026-11-21 · Mkt cap 104.41M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Kewaunee Scientific Corporation DCF and intrinsic value
InvestorsCraft values KEQU with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from KEQU’s statements →
Kewaunee Scientific Corporation Graham Number
Graham Number: $45.04d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $282M | $240.5M | $203.8M | $219.5M | $168.9M |
| Operating income | $16.7M | $17.8M | $18.3M | $3.63M | -$-2.61M |
| Net income | $9.62M | $11.4M | $18.8M | $1.36M | -$-6M |
| EPSd | $3.23M | $3.83M | $6.38M | $469K | -$-2.15M |
| Operating cash flow | $18.6M | $14.8M | $19.6M | -$-3.79M | -$-7.88M |
| Capital expenditure | -$-3.94M | -$-2.17M | -$-4.37M | -$-4.15M | -$-1.91M |
| Free cash flow | $14.7M | $12.6M | $15.2M | -$-7.94M | -$-9.79M |
| Total assets | $178.3M | $194.7M | $134.8M | $118.9M | $118.8M |
| Total debt | $30.2M | $50.2M | $11M | $12.9M | $67.6M |
| Net debt | $18.6M | $35.2M | -$-12.27M | $4.84M | $63.1M |
| Total equity | $76.8M | $66.3M | $56.2M | $38.5M | $36.2M |
| Cash and short-term investments | $11.6M | $14.9M | $23.3M | $8.08M | $4.43M |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $282M | $240.5M | $203.8M | $219.5M | $168.9M |
| Cost of revenue | $201.6M | $171.6M | $151.7M | $183.9M | $144.7M |
| Gross profit | $80.4M | $68.9M | $52.1M | $35.6M | $24.2M |
| Research and development expenses | $900K | $0.00 | $920K | $1.01M | $990K |
| Selling, general and administrative expenses | $63.7M | $51.1M | $38M | $29.9M | $26.8M |
| Other expenses | -$-900K | $51.1M | -$-5.1M | $30.2M | $26.8M |
| Operating expenses | $63.7M | $51.1M | $33.8M | $30.2M | $26.8M |
| Cost and expenses | $265.3M | $222.7M | $185.5M | $214.1M | $171.5M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $3.86M | $3.21M | $1.8M | $1.73M | $630K |
| Depreciation and amortization | $6.28M | $4.76M | $3.12M | $2.87M | $2.77M |
| Ebitda | $23.9M | $22.8M | $18M | $8.16M | $920K |
| Operating income | $16.7M | $17.8M | $18.3M | $3.63M | -$-2.61M |
| Total other income/expenses, net | -$-2.98M | -$-2.97M | -$-5.16M | -$-870K | $120K |
| Income before tax | $13.7M | $14.8M | $13.1M | $4.5M | -$-2.48M |
| Income tax expense | $3.27M | $3.2M | -$-5.94M | $3.14M | $3.52M |
| Net income | $9.62M | $11.4M | $18.8M | $1.36M | -$-6M |
| Weighted average shares outstanding | $2.86M | $2.86M | $2.88M | $2.82M | $2.79M |
| Weighted average diluted shares outstanding | $2.98M | $2.98M | $2.94M | $2.9M | $2.79M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $11.6M | $14.9M | $23.3M | $8.08M | $4.43M |
| Net receivables | $58.7M | $62.4M | $45.1M | $46.1M | $54.7M |
| Inventory | $30.5M | $32.9M | $20.7M | $21.9M | $23.8M |
| Total current assets | $105.4M | $118.4M | $96.8M | $87.9M | $91.6M |
| Property, plant and equipment, net | $33.2M | $36.1M | $25.1M | $25.6M | $22.7M |
| Goodwill and intangible assets | $28.8M | $30.3M | $0.00 | -$-1.1M | -$-1.22M |
| Long-term investments | $2.72M | $1.86M | $1.56M | $1.1M | $1.22M |
| Total non-current assets | $72.9M | $76.3M | $38M | $31M | $27.2M |
| Total assets | $178.3M | $194.7M | $134.8M | $118.9M | $118.8M |
| Accounts payable | $22.5M | $27M | $23.3M | $23.6M | $27.3M |
| Short-term debt | $8.81M | $7.26M | $5.33M | $5.64M | $3.61M |
| Deferred revenue | $0.00 | $6.07M | $4.37M | $4.1M | $3.53M |
| Total current liabilities | $48.4M | $53.7M | $40.8M | $40.1M | $42.3M |
| Long-term debt | $21.4M | $42.9M | $5.67M | $63.6M | $64M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | -$-940K | $0.00 |
| Total non-current liabilities | $53.2M | $74.7M | $37.8M | $40.4M | $40.3M |
| Capital lease obligations | $10.4M | $12.3M | $7.9M | $37.5M | $36.6M |
| Total liabilities | $101.5M | $128.4M | $78.6M | $80.4M | $82.6M |
| Common stock | $7.42M | $7.35M | $7.27M | $7.08M | $6.98M |
| Retained earnings | $68.5M | $58.9M | $47.5M | $28.8M | $28M |
| Accumulated other comprehensive income (loss) | -$-4.61M | -$-3.8M | -$-3.38M | -$-3.44M | -$-3.74M |
| Total equity | $76.8M | $66.3M | $56.2M | $38.5M | $36.2M |
| Total investments | $2.72M | $1.86M | $1.56M | $1.1M | $1.22M |
| Total debt | $30.2M | $50.2M | $11M | $12.9M | $67.6M |
| Net debt | $18.6M | $35.2M | -$-12.27M | $4.84M | $63.1M |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | $10.5M | $11.6M | $18.8M | $1.36M | -$-6M |
| Depreciation and amortization | $6.28M | $4.76M | $3.12M | $2.87M | $2.77M |
| Stock-based compensation | $2.13M | $1.44M | $1.03M | $890K | $730K |
| Change in working capital | -$-190K | -$-2.02M | $3.21M | -$-9.54M | -$-5.59M |
| Accounts receivable | $3.3M | -$-6.74M | $740K | -$-4.95M | -$-8.46M |
| Inventory | $2.32M | $3.35M | $1.21M | $1.91M | -$-7.28M |
| Accounts payable | $0.00 | $0.00 | $0.00 | -$-5.56M | $11.9M |
| Net cash provided by operating activities | $18.6M | $14.8M | $19.6M | -$-3.79M | -$-7.88M |
| Investments in property, plant and equipment | -$-3.94M | -$-2.17M | -$-4.37M | -$-4.15M | -$-1.91M |
| Acquisitions, net | $0.00 | -$-28.73M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-3.94M | -$-30.9M | -$-4.37M | -$-4.15M | -$-1.91M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-670K | -$-1.6M | -$-2M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-19.33M | $7.41M | -$-3.01M | $14.9M | $11M |
| Net change in cash | -$-5.55M | -$-8.77M | $12.1M | $6.92M | $1.16M |
| Cash at end of period | $11.6M | $17.2M | $25.9M | $13.8M | $6.89M |
| Operating cash flow | $18.6M | $14.8M | $19.6M | -$-3.79M | -$-7.88M |
| Capital expenditure | -$-3.94M | -$-2.17M | -$-4.37M | -$-4.15M | -$-1.91M |
| Free cash flow | $14.7M | $12.6M | $15.2M | -$-7.94M | -$-9.79M |
Line items
Line items
Line items
About Kewaunee Scientific Corporation
Kewaunee Scientific Corporation, established in 1906 and based in Statesville, North Carolina, specializes in providing custom furniture and infrastructure systems for scientific, medical, and technical settings. The company manages its operations through distinct domestic and international divisions. Its extensive product line features diverse furniture options crafted from steel, wood, and laminate, along with specialized equipment like fume hoods, biological safety cabinets, laminar flow systems, and ductless hoods. Kewaunee also offers versatile modular and column systems, mobile workstations, carts, durable epoxy resin worksurfaces, sinks, and various accessories, all supported by comprehensive design assistance. These solutions serve a broad client base: Laboratory products are essential for chemistry, physics, biology, and other general science research conducted in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, governmental, and healthcare industries. Technical products are utilized in facilities manufacturing computers and light electronics, as well as by those requiring furniture for computer and networking setups. Laminate casework applications extend to educational, healthcare, and industrial environments. The corporation primarily distributes its offerings through a network of independent dealers, its own subsidiary companies, and a major national distributor.
- CEO
- Thomas David Hull
- Employees
- 1.23K
- Beta
- 0.71
Explore
Frequently asked questions
What is the intrinsic value of Kewaunee Scientific Corporation (KEQU)?
Kewaunee Scientific Corporation (KEQU) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is KEQU undervalued?
KEQU trades at a price of $33.55 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.